Phase IIa
Rivus Advances in Obesity-Related Heart Failure with Mid-Stage Success of HU6
Rivus Pharmaceuticals, HU6, obesity-related heart failure, Phase IIa HuMAIN trial, controlled metabolic accelerator, muscle-preserving weight loss
Praxis’ Mid-Stage Triumph Propels Advancement of Novel Epilepsy Drug
Praxis Precision Medicines, PRAX-628, Functionally Selective Small Molecule, Hyperexcitable State of Sodium Channels, Adult Focal Onset Epilepsy Treatment, Phase IIa Proof of Concept Study Success, Second Half of 2024 Efficacy Study Planned